ClinicalTrials.gov (NCT00770328) The Effects of Pentoxifylline on PAI-1 in an Obese Population. U.S. National Institutes of Health.
Ref 537833
Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst. 1995 May 17;87(10):751-6.
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.